REGENXBIO/$RGNX

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About REGENXBIO

Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.

Ticker

$RGNX
Primary listing

Industry

Biotechnology

Employees

353

ISIN

US75901B1070

REGENXBIO Metrics

BasicAdvanced
$432M
-
-$3.10
1.11
-

What the Analysts think about REGENXBIO

Analyst ratings (Buy, Hold, Sell) for REGENXBIO stock.

Bulls say / Bears say

REGENXBIO's submission of a Biologics Licensing Application (BLA) for clemidsogene lanparvovec (RGX-121) positions the company for potential FDA approval in the second half of 2025, marking a significant milestone in their gene therapy pipeline. (REGENXBIO Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Updates)
The strategic partnership with Nippon Shinyaku, which includes a $110 million upfront payment and up to $700 million in milestone payments, significantly strengthens REGENXBIO's financial position and commercial prospects. (REGENXBIO Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Updates)
Positive interim biomarker data from the AFFINITY DUCHENNE® trial of RGX-202 gene therapy for Duchenne Muscular Dystrophy indicates favorable safety and efficacy, supporting the potential for accelerated development timelines. (REGENXBIO REPORTS POSITIVE BIOMARKER DATA FROM AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPY)
REGENXBIO reported a net loss of $227.1 million for the year ended December 31, 2024, indicating ongoing financial challenges despite revenue streams. (REGENXBIO Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Updates)
The company's revenue decreased to $83.3 million in 2024 from $90.2 million in 2023, primarily due to a decline in Zolgensma royalty revenues, which could impact financial stability. (REGENXBIO Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Updates)
Despite a strong cash position, the company's cash, cash equivalents, and marketable securities decreased to $244.9 million as of December 31, 2024, from $314.1 million the previous year, reflecting increased cash burn. (REGENXBIO Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Updates)
Data summarised monthly by Lightyear AI. Last updated on 9 Jun 2025.

REGENXBIO Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

REGENXBIO Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $RGNX

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs